Last updated: July 18, 2026
Executive summary: Avanir Pharmaceuticals Inc. v. Par Pharmaceutical Inc., No. 1:11-cv-00705, is a Hatch-Waxman patent infringement dispute tied to Par’s generic entry strategy against Avanir’s branded product(s). Based on the case caption and docket number alone, a complete, decision-grade litigation summary is not possible: the asserted patents, the underlying FDA Orange Book listing(s), the filing timeline of any Abbreviated New Drug Application (ANDA), the procedural posture (dismissal, settlement, or judgment), and the final disposition are not identifiable from the provided information.
What claims and patents were asserted in Avanir v. Par Pharmaceutical Inc. 1:11-cv-00705?
Answer (required for litigation analysis): The asserted patent numbers, patent claims, and asserted drug listing are not specified in the provided input, so the infringement theory and claim construction posture cannot be accurately summarized.
Which Avanir product(s) and Orange Book patent listings drove the case?
Answer: Not determinable from the provided information.
What FDA Orange Book entries were at issue?
Answer: Not determinable from the provided information.
What dosage forms and strengths were implicated?
Answer: Not determinable from the provided information.
When was the Hatch-Waxman trigger in 1:11-cv-00705 and what paragraph IV (or other) notice was used?
Answer: The type and date of any notice letter (Paragraph IV vs. Paragraph I/III) and the ANDA filing date cannot be determined from the provided information.
What was the litigation timeline from notice to filing?
Answer: Not determinable.
What were the key dates (ANDA submission, notice date, complaint filing, answer, claim construction)?
Answer: Not determinable.
How did Par’s generic entry plan relate to Avanir’s branded exclusivities and patent terms?
Answer: The drug and patent estate are not stated in the provided input, so exclusivity and expiration leverage cannot be analyzed.
What exclusivity was at stake (marketing exclusivity, NCE, pediatric, 30-month stay)?
Answer: Not determinable.
When did asserted patents expire (and which claims would have blocked generic approval)?
Answer: Not determinable.
What did the court decide in Avanir v. Par Pharmaceutical Inc., 1:11-cv-00705?
Answer: Case disposition is not provided, so outcomes (dismissal, summary judgment, trial verdict, settlement with stipulated injunction or launch date) cannot be stated.
Did the court enter an injunction or find invalidity/noninfringement?
Answer: Not determinable.
What settlements or licensing terms were reached?
Answer: Not determinable.
What is the procedural posture (motions, claim construction, summary judgment, trial) in 1:11-cv-00705?
Answer: Not determinable from the provided information.
What motions were filed (Rule 12, venue/transfer, preliminary injunction, JMOL, Daubert)?
Answer: Not determinable.
How strong is Avanir’s patent estate for the drug(s) involved, and what generic entry risks exist?
Answer: Cannot be quantified without the asserted patents, their priority dates, expiration dates, and prosecution/claim scope.
What patents typically protect Avanir-branded products in litigation like this?
Answer: Not case-specific without the asserted patent list.
Formulation patents
Answer: Not determinable.
Method-of-use patents
Answer: Not determinable.
Manufacturing or process patents
Answer: Not determinable.
Which jurisdictions and courts did the case affect, and did it have consolidation or related actions?
Answer: Venue is implied only by the docket identifier; consolidation and related-file tracking is not possible from the provided input.
Was there any related case against other ANDA filers or co-defendants?
Answer: Not determinable.
Orange Book status and FDA approval risk: what did Avanir need to prove in 1:11-cv-00705?
Answer: The FDA listing(s) and risk posture depend on the ANDA and the Orange Book patents; these are not supplied.
What is the Orange Book status of the Avanir listing(s) tied to this case?
Answer: Not determinable from the provided information.
Comparable Avanir v. generic litigation: how does 1:11-cv-00705 fit the pattern?
Answer: Without the asserted product/patents and outcome, no pattern comparison can be made in a way that is accurate and useful for licensing or infringement risk scoring.
Key Takeaways
- The docket number and party names alone do not provide the asserted patent list, FDA/Orange Book linkage, ANDA/notice type, or final disposition required for a litigation summary and enforceability analysis.
- No decision-grade conclusions on claim strength, invalidity risks, injunction likelihood, or launch-date exposure can be produced from the provided information.
FAQs
-
What does a Hatch-Waxman Paragraph IV notice require for an Avanir v. Par-style case?
Not answerable without the notice type and asserted patent details.
-
How do courts evaluate noninfringement in method-of-use patent cases in generic challenges?
Not case-specific without the asserted claims.
-
What Orange Book listing triggers the 30-month stay and how is it identified in litigation?
Not determinable without the Orange Book listing tied to the docket.
-
Do settlements in Avanir v. Par generics typically include stipulated launch dates or injunction terms?
Not determinable without the settlement record.
-
What validity arguments (ODP, obviousness, written description) are most common in ANDA patent suits like 1:11-cv-00705?
Not determinable without the asserted patents and the court’s rulings.
References
- No sources were provided or identifiable from the prompt to support citations.
